Key result
Sacubitril/valsartan has shown potential in small observational studies to improve cardiac structure and function in patients with cancer therapy-related cardiac dysfunction.
Why the study?
Patients with cancer therapy-related cardiac dysfunction were excluded from pivotal sacubitril/valsartan trials, and the contemporary literature on its potential benefit in the cardio-oncology setting needed description.
Does sacubitril/valsartan improve cardiac structure and function in patients with cancer therapy-related cardiac dysfunction?
Does sacubitril/valsartan improve cardiac structure and function in patients with cancer therapy-related cardiac dysfunction?
This review highlights the potential of sacubitril/valsartan for treating cancer therapy-related cardiac dysfunction, emphasizing the need for large-scale prospective trials.
Hypothesis-generating for sacubitril/valsartan in cancer therapy-related cardiac dysfunction; prospective trials needed before clinical adoption.
Cardiotoxicity is the most dramatic complication of cancer therapies, and it results in the cessation of potentially life-saving antitumor treatment regimens and a poor survival prognosis in a nonnegligible proportion of patients. Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of cancer therapy-related cardiac dysfunction (CTRCD), whereas their roles in the prevention of cardiotoxicity are unclear. Sacubitril/valsartan, which is an angiotensin receptor-neprilysin inhibitor, has been shown to be advantageous over ACEIs in heart failure patients with reduced ejection fraction for further the reduction of cardiovascular death or rehospitalization. However, patients with CTRCD were excluded from pivotal trials involving sacubitril/valsartan. Although several small observational studies have observed excellent performance in improving cardiac structure and function in patients with CTRCD, large-scale prospective clinical studies are required to confirm these results. In this review, we described the contemporary literature concerning the potential benefit of sacubitril/valsartan in the cardio-oncology setting.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2023) conducted a review in Cancer therapy-related cardiac dysfunction (CTRCD). Sacubitril/valsartan was evaluated. Sacubitril/valsartan has shown potential in small observational studies to improve cardiac structure and function in patients with cancer therapy-related cardiac dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: